Context: Uterine leiomyomas (fibroids) are the most common benign tumors in women. Recently, three populations of leiomyoma cells were discovered on the basis of CD34 and CD49b expression, but molecular differences between these populations remain unknown.
Objective: To define differential gene expression and signaling pathways in leiomyoma cell populations. Patients: Eight African American women.
Interventions: None
Main Outcomes Measures: Gene expression patterns, cell proliferation, and differentiation.
Results: A total of 1164 genes were differentially expressed in the three leiomyoma cell populations, suggesting a hierarchical differentiation order whereby CD34 + /CD49b + stem cells differentiate to U terine leiomyomas are benign tumors that arise from the monoclonal expansion of uterine smooth muscle cells (1) . Symptoms of leiomyomas include irregular and heavy menstrual bleeding, pelvic pain, pressure symptoms on the bowel and bladder, and recurrent pregnancy loss and infertility. Leiomyomas have a considerable public health impact; they are estimated to cause symptoms in up to 30% of reproductive-age women, with more than 200,000 surgeries performed in the United States annually to treat leiomyomas, leading to an annual cost of $5.9 to $34.4 billion (1). Despite the prevalence of leiomyomas and their impact on women's health, there are currently no US Food and Drug Administration-approved medications for the long-term treatment of leiomyomas. Additionally, currently available medications are limited by side effects, and tumors tend to recur upon discontinuation of treatment (2) . Improving our knowledge of the specific etiology and pathophysiology of leiomyomas is necessary to develop better therapies.
Recently, a small population of cells with stem cell-like features was discovered in uterine leiomyomas using the side population technique (3, 4) . We demonstrated that these cells were necessary for steroid-dependent tumor growth, and grafts containing leiomyoma stem cells grew into significantly larger tumors when placed underneath mouse kidney capsules compared with grafts without stem cells (3) . Unfortunately, the side population technique is expensive and sensitive to slight staining variations, and the Hoechst stain is toxic to cells (5) . We recently reported an alternative approach to isolating leiomyoma stem cells using flow cytometry on the basis of expression of the cell surface markers CD34 and CD49b (6) 
Materials and Methods

Tissue acquisition and processing
Human uterine leiomyoma tissue was obtained at the time of myomectomy or hysterectomy from eight premenopausal African American women (age range, 33 to 49 years) who provided informed consent. Most uteri contained multiple fibroid tumors. The size of the tumors biopsied for this study varied from 4.8 cm to 21.3 cm. The procedure was conducted at Northwestern Memorial Prentice Women's Hospital under a protocol approved by the Institutional Review Board of Northwestern University. No subjects had received any hormonal or gonadotropin-releasing hormone agonist or antagonist treatments in the prior 6 months. Tissues were dissociated and cells isolated as previously described (7).
Cell culture
All experiments were performed in cells isolated from fresh tissues and cultured without passaging. Leiomyoma cells were cultured on cell culture plates and in rolling suspension using a low profile roller (IBI Scientific, Peosta, IA) in a humidified atmosphere in 5% CO 2 at 37°C. For IGF2 treatment, pro-IGF2 peptide (Humanzyme, Chicago, IL) at a concentration of 10, 50, or 100 ng/mL was added with 0.1% bovine serum albumin in phenol red-free and serum-free Dulbecco's modified Eagle medium. Control cells were treated with vehicle (phosphatebuffered saline) with 0.1% bovine serum albumin in phenol red-free and serum-free Dulbecco's modified Eagle medium. For inhibition of the extracellular signal-regulated kinase (ERK) pathway, 10 mM mitogen-activated protein kinase kinase inhibitor U0126 was added to the culture media 2 hours prior to adding IGF2 or vehicle. This concentration and incubation period of U0126 have been previously described (8) .
Antibody-based cell sorting
Cells were incubated with fluorescently labeled antibodies against CD45, CD34, and CD49b to identify CD34
2 , and CD34 2 /CD49b 2 populations, while excluding CD45 + (hematopoietic) cells, as previously described (7). All antibodies used are listed in Supplemental Table 1 . Cells were either analyzed using the LSR Fortessa system (BD Biosciences, San Jose, CA) or sorted and collected using a FACSAria cell sorter (BD Biosciences). The approximate yield is 0.5 3 10 6 viable stem cells from 20 g of leiomyoma tissue, which can be sorted within 3 hours using FACSAria.
Microarray and data analysis
Microarray was performed in triplicate using RNA isolated from leiomyoma cells from eight premenopausal African American women. After sorting on the basis of CD34 and CD49b expression, total RNA was extracted from each population of leiomyoma cells using the RNAeasy mini kit or micro kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The micro kit was used for samples containing less than 100,000 cells. The Illumina Human HT-12 microarray platform (Illumina, San Diego, CA) was used for expression profiling. Hierarchical clustering and principal component analysis were performed to assess sample relationships and variability. The fold-change threshold was set to 61.5, with a false discovery rate , 5%. Pathway analysis was performed using MetaCore (Thomson Reuters, New York, NY), the Kyoto Encyclopedia of Genes and Genomes, and Gene Ontology.
qRT-PCR
Total RNA was isolated from either cultured or sorted leiomyoma cells using the RNAeasy mini kit or micro kit according to the manufacturer's instructions (Qiagen). Complementary DNA was synthesized from 1 mg RNA using qScript cDNA supermix (Quantabio, Beverly, MA) according to the manufacturer's instructions. Quantitative real-time PCR (qRT-PCR) was performed as previously described (9) . Insulinlike growth factor 1 (IGF1), IGF2, IGF binding protein 3 (IGFBP3), insulin receptor A (IR-A), IGF1 receptor (IGF1R), and IGF2 receptor (IGF2R) messenger RNA (mRNA) levels were determined by qRT-PCR using the ABI TaqMan gene expression system (Applied Biosystems, Foster City, CA). All primers used in this study are listed in Supplemental Table 2 . Gene expression data were normalized to TBP or HPRT1. Samples were processed in the 7900HT Fast Real-Time PCR system (Applied Biosystems) and data were collected with SDS 2.3 software (Applied Biosystems).
Immunoblotting
Protein from leiomyoma cells was isolated using a radioimmunoprecipitation assay lysis and extraction buffer (Thermo Scientific, Waltham, MA). Protein from cultured cells was quantified using the BCA Protein Assay (Thermo Scientific), and 20 mg of protein was diluted with reducing 4X LDS Sample Buffer (Life Technologies, Carlsbad, CA), electrophoresed on 4% to 12% Novex Bis-Tris polyacrylamide precast gels (Life Technologies), and transferred onto polyvinyl difluoride membranes. For sorted cells, equal protein loading was estimated using cell counts as reported by the FACSAria cell sorter, with protein isolated from 150,000 cells in each group and protein separation performed as described previously. Membranes were blocked with 5% milk in Tris-buffered saline (TBS) and 0.2% Tween-20 and probed with primary antibody overnight at 4°C. Horseradish peroxidase-conjugated secondary antibodies (Cell Signaling, Danvers, MA) were diluted in 5% milk at 1:6000 and incubated with membranes at room temperature for one hour. The membranes were washed in TBS with 0.2% Tween-20 three times, followed by one wash in TBS. Femto (Thermo Scientific) or Luminata Crescendo (EMD Millipore, Darmstadt, Germany) was used for detection. Film was developed in a Konica Minolta developer (Maitland, FL), and Image Studio Lite (LI-COR Biosciences, Lincoln, NE) software was used to quantify immunoblots.
Cell proliferation assay
A Click-iT 5-ethynyl-2 0 -deoxyuridine (EdU) Alexa Fluor 488 Imaging Kit (Life Technologies) was used to measure cell proliferation after overnight treatment of cells in rolling suspension with vehicle or 100 ng/mL IGF2. EdU incorporation was allowed to occur for 1.5 to 2 hours at 37°C, followed by antibody staining for CD34 and CD49b. The Click-iT reaction was performed according to the manufacturer's instructions.
Analysis was performed using the LSR Fortessa System (BD Biosciences). Cells were also counted after overnight treatment, and fold change from vehicle to IGF2-treated cells was calculated.
Statistical analysis
All experiments were performed using primary cells from at least three subjects. Data were analyzed using paired Student t tests or repeated measures analysis of variance with Bonferroni correction for three pairwise comparisons, using Microsoft Excel and SAS 9.2 (SAS Institute, Cary, NC). The microarray data were analyzed using multiple t tests, with differential expression defined as fold change . ). Intriguingly, pathway analysis also revealed overrepresentation of multiple pathways in which IGF signaling is known to play a role, including proliferation, apoptosis, epithelial-to-mesenchymal transition, and pathways in cancer and glucose regulation. Additionally, genes from the TGF and WNT signaling pathways were differentially expressed, consistent with prior literature on uterine leiomyomas.
Microarray profiling indicated overexpression of the growth factors IGF1 and IGF2 in CD34 + /CD49b 2 cells, whereas the binding protein IGFBP3, which regulates the availability of these growth factors, was overexpressed in CD34 + /CD49b + stem cells. qRT-PCR verified the differential expression of IGF1, IGF2, IGFBP3, and the IGF receptors IGF1R, IGF2R, and IR-A [ Fig. 2(a) and (b) ]. IR-A was overexpressed, whereas IGF1R expression was lower, in CD34 + /CD49b + stem cells vs CD34 2 / CD49b 2 cells (15-fold and 0.4-fold, respectively; P , 0.017).
IGF2R mRNA levels were not statistically different between the three populations. Given the striking differences in IGF2 mRNA levels (up to 150-fold), and the paucity of data on the biologic role of IGF2 in uterine leiomyomas, we focused on the role of IGF2 in leiomyoma cells.
IGF2 increases proliferation in uterine leiomyoma cells, but does not affect apoptosis
We determined the basic biologic functions of IGF2 in uterine leiomyoma by culturing primary leiomyoma cells for 48 hours with vehicle vs IGF2. Immunoblot analysis showed a dose-dependent increase in levels of the proproliferation protein PCNA [ Fig. 3(a) ]. IGF2 had no effect on the levels of the antiapoptotic proteins BCL2 or BCLXL (data not shown). Cell count increased 1.37-fold (P , 0.001) after overnight culture in rolling suspension with 100 ng/mL IGF2 compared with vehicle [ Fig. 3(b) ]. When leiomyoma cells were sorted on the basis of CD34 and CD49b expression and then treated with vehicle or IGF2, the rate of EdU incorporation into DNA, a measure of proliferation, increased in all three populations by approximately 20% to 30% compared with vehicle [ Fig. 3(c) 
IGF2 activates the mitogen-activated protein kinase/ERK pathway in leiomyoma cells
To determine the downstream biologic effects of IGF2 in leiomyoma cells, we performed a time course study in which unsorted leiomyoma cells were incubated with 100 ng/mL IGF2 for 0, 5, 15, 30, 60, and 90 minutes. IGF2 activated the mitogen-activated protein kinase/ERK pathway, with ERK phosphorylation observed as soon as 15 minutes, detected using antibodies that recognize both ERK1 and ERK2 [ Fig. 4(a) ]. Blockage of the ERK pathway with a 2-hour preincubation with the inhibitor compound Although microarray studies have consistently shown IGF2 to be overexpressed in leiomyoma compared with myometrium (10), there are relatively few data in the literature on the role of IGF2 in leiomyoma pathogenesis. In 1993, Giudice et al. (11) reported that estradiol action on the growth of leiomyoma was mediated by IGF1, but not IGF2, and that IGF2 expression was unaffected by hormonal status. Shortly thereafter, Strawn et al. (12) reported that IGF1, but not IGF2, increased leiomyoma proliferation. These disparate findings may be explained by the differences in scale between our study and previous studies. Whereas previous studies examined the global effects of steroid hormone and IGF on unsorted leiomyoma cells, our research focused on the role of IGF in stem cells compared with more mature cell populations within leiomyoma tissue.
Other studies have similarly shown that IGF1 increases both survival and proliferation and decreases apoptosis in leiomyoma (13) (14) (15) , but evidence suggests that IGF1 and IGF2 signal through different pathways (16) , and data on the effects of IGF1 may not be applicable to IGF2. Leiomyoma tissue from women treated with gonadotropin-releasing hormone agonist secretes less IGF1 and IGF2 compared with leiomyoma tissue from women without treatment (17) , suggesting that there may be some steroid hormone-mediated regulation of IGF2 expression. Most recently, Di Tommaso et al. (18) reported that IGF2 overexpression in leiomyoma is highly correlated with missense mutations in the mediator complex subunit 12 (MED12) gene, suggesting that there are possibly separate and independent pathways of leiomyoma pathogenesis. Although this study did not determine the MED12 status of the included leiomyoma tissue, the effects of IGF2 in leiomyoma tissue harboring MED12 mutations vs tumors without MED12 mutations could be an interesting area of future study.
Although there is a paucity of data on the role of IGF2 or IR-A in leiomyoma, their involvement in cancer and There were no significant differences in IGF2R expression between the three populations. Lowercase letters denote statistically significant differences between bars bearing a given letter within each graph (P , 0.017). Note the differences in scale for fold change between graphs.
stem cell biology has been well established. Cancer cells overexpress IR-A, with increased affinity for IGF2, autocrine production of IGF2, and preferential activation of the ERK pathway (19, 20) . Several malignancies also overexpress IGF2, including colorectal, adrenal, thyroid, prostate, breast and ovarian carcinomas, leukemia, and sarcomas. Elevated IGF2 production is often correlated with poorer prognosis (19, 20) . Moreover, IGF2 produced by human embryonic stem cell-derived fibroblasts is necessary for self-renewal and pluripotency of embryonic stem cells, and IR-A is overexpressed in both cancer and stem cells (19, 20) . It is possible that embryonic stem cell-derived fibroblasts are analogous to the CD34 + /CD49b 2 (intermediary) leiomyoma cell population in our study; this will be explored further in the future. IGF2 acts through IR-A in promoting self-renewal and stemness of neural stem cells (21) . Also consistent with our data that show higher expression of IR-A in the leiomyoma stem cell population, IR-A is significantly overexpressed in neural stem cells compared with neurons, whereas IGF1R is significantly underexpressed (21) . Thus, with respect to IGF signaling, the leiomyoma stem and intermediary cell populations seem to exhibit a paracrine interaction pattern consistent with other tissues. There are some limitations to our study. The use of primary tissues is a strength in that the experiments are closer to in vivo conditions than those using cell lines, but there is also greater sample-to-sample variability inherent to individual patients, making statistical analysis challenging. We overcame this challenge by sampling a relatively large number of patients (n = 8) and using a large total sample size (n = 24) for microarray profiling, and by electing to use tissues from only African American women to minimize race-dependent variation. Additionally, given the small percentage of stem cells in leiomyoma tissue, we were limited to using large tumors to obtain sufficient cell numbers to perform our experiments. This limited our ability to restrict included tissue by patient age or phase of menstrual cycle, although all included subjects were premenopausal and no subjects had received any hormonal or gonadotropin-releasing hormone agonist or antagonist treatments in the prior 6 months. The ability of IGF2 to induce leiomyoma proliferation was decreased significantly by blocking the ERK pathway; however, the role of IR-A remains to be demonstrated mechanistically. Future studies will focus on disrupting IR-A to address this question. Finally, we are still refining our methods for long-term culture of stem cells and maintenance of their dedifferentiated status, so our experiments were limited to short culture periods after sorting the leiomyoma cells into the three populations. As methods for culturing and studying leiomyoma stem cells evolve, we should be able to study the pathways involved in their function in greater detail.
Overall, this study presents a genome-wide comparison between three populations of leiomyoma cells, including leiomyoma stem cells, as well as evidence on the importance of IGF2 signaling and IR-A in leiomyoma stem cells and tumor growth. The IGF2 system is likely one of the paracrine pathways involved in leiomyoma stem cell function. Future studies should use this microarray data to further delineate the role of the three populations in leiomyoma pathogenesis and interaction between the populations. Additionally, because IGF2 is primarily regulated by imprinting, methylation studies may help explain some of the differences in expression between cell types. Given that IGF2 plays a relatively minor role in normal adult physiology (20) , it is an attractive therapeutic target. There are already multiple studies underway investigating strategies to target IGF2 expression or function as anticancer treatment (20) . It would be interesting to investigate whether any of these potential therapeutics are compatible with intrauterine delivery to more precisely target leiomyomas. Increasing our understanding of leiomyoma stem cell pathophysiology is important because the ability to target pathways necessary for stem cell action may lead to the development of treatments that can not only shrink existing leiomyomas, but also prevent the development of new tumors.
